Abstract
Interleukin-2 receptor (IL-2R) can be detected in serum. We estimated the IL-2R in the serum of 78 women, of whom 30 were diagnosed as having malignant ovarian tumours, five had non ovarian tumours, one had a negative second look laparotomy, 11 had benign ovarian tumours, three had uterine fibroids and 28 were age-matched controls. The results indicated that the serum IL-2R of these patients was significantly elevated in ovarian cancer patients compared to both controls (P < 0.0001) and benign ovarian tumours (P < 0.0002). There were no significant differences in IL-2R levels between stage of disease and degree of differentiation within the ovarian tumour group.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Owens, O., Taggart, C., Wilson, R. et al. Interleukin-2 receptor and ovarian cancer. Br J Cancer 68, 364–367 (1993). https://doi.org/10.1038/bjc.1993.341
Issue Date:
DOI: https://doi.org/10.1038/bjc.1993.341
This article is cited by
-
Levels of serum-soluble receptor for interleukin-2 in patients with colorectal cancer
Surgery Today (1998)
-
Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma
Journal of Endocrinological Investigation (1994)